Touchstone
Last syncOct 31, 2026, 6:54 PM ET

COLL

Collegium Pharmaceutical, Inc Health Care Pharmaceutical Preparations Russell 3000
$23.80Close $754.6MMarket cap $21.53 – $49.8452-week range Nov 5, 2026Next report · before the open

Highlights

Cautions

  • Not in an uptrend 1 of 8 trend conditions
  • Lagging the market RS 6 · weaker than 94% of stocks over 12 months
  • Far from its high 52% below its 52-week high
  • Earnings shrinking EPS −251% year on year
  • Results soon Nov 5, 2026, in 4 days
  • Financial distress Altman Z″ in the distress zone

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 6, 2026
Off 12-month high 52%
1wk up 3.7% price change
1mo up 9.1% price change
12-month return down 33% market up 11% · its own down 42%
F-score 5 / 9 Mixed
Altman Z 1.26 Elevated risk
P/E 12.0× price / earnings
PEG — P/E / EPS growth
P/B 2.5× price / book
Earnings yield up 16.9% EBIT / enterprise value
Cheaper than 87% of the market · markedly cheap
Revenue growth up 24% year on year
EPS growth down 251% latest quarter · -643 pts
Sales growth up 6% latest quarter · -3 pts
ROE up 24% return on equity
Free cash margin up 42% $327.6M FCF
D/E 1.80 long-term debt / equity
Net debt / EBITDA 1.7×
Interest cover —EBIT / interest
Piotroski tests
  • profitability slipped from last year
  • issued more shares
  • gross margin narrowed
  • assets working less efficiently
  • profitable on its assets
  • generating cash from operations
  • profits backed by cash
  • reduced long-term debt
  • short-term liquidity improved

Trade setup

ATR% 3.5% $0.84 a day · 2×ATR $22.12
RS 6 / 99 vs the universe
Trend 1 / 8 trend template
Relative volume 0.5× vs 50-day average
Up/down volume 0.90 50 sessions
Implied move — no option chain · report Nov 5, 2026
Trend template · 1 of 8
  • Price above the 50-day average: passes

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged
  • Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Last reported Aug 6, 2026
Last shock Aug 6, 2026-19% in one session4.8× volumeon results-18% since

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $780.6M +24% on FY2024
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $310.0M FY2021 · $276.9M FY2022 · $463.9M FY2023 · $566.8M FY2024 · $631.4M FY2025 · $780.6M
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $63.0M -9% on FY2024
-$25M $0 $100M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $26.8M FY2021 · $72.0M FY2022 · -$25.0M FY2023 · $48.0M FY2024 · $69.0M FY2025 · $63.0M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $327.6M +61% on FY2024
$0 $500M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $88.4M FY2021 · $101.6M FY2022 · $122.6M FY2023 · $274.3M FY2024 · $203.3M FY2025 · $327.6M
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross 59%
  • Net 8%
  • Free cash 42%
0% 100% FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Gross 58% · Net 9% · Free cash 29% FY2021 · Gross 54% · Net 26% · Free cash 37% FY2022 · Gross 45% · Net -5% · Free cash 26% FY2023 · Gross 58% · Net 8% · Free cash 48% FY2024 · Gross 60% · Net 11% · Free cash 32% FY2025 · Gross 59% · Net 8% · Free cash 42%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $310.9M net debt
  • Cash
  • Long-term debt
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Cash $174.1M · Long-term debt $110.0M FY2021 · Cash $186.4M · Long-term debt $61.7M FY2022 · Cash $173.7M · Long-term debt $397.6M FY2023 · Cash $238.9M · Long-term debt $221.7M FY2024 · Cash $70.6M · Long-term debt $550.7M FY2025 · Cash $231.3M · Long-term debt $542.1M
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 31.71m -8.4% since FY2020
34.61m 31.44m FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · 34.61m FY2021 · 33.66m FY2022 · 33.85m FY2023 · 31.87m FY2024 · 31.44m FY2025 · 31.71m
  FY2020Dec 31, 2020 FY2021Dec 31, 2021 FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $310.0M $276.9M $463.9M $566.8M $631.4M $780.6M
Gross margin 58% 54% 45% 58% 60% 59%
Operating income $56.2M $17.6M $33.3M $167.0M $169.9M $179.6M
Net income $26.8M $72.0M -$25.0M $48.0M $69.0M $63.0M
Net margin 9% 26% -5% 8% 11% 8%
Earnings per share $0.76 $1.75 -$0.74 $1.15 $1.71 $1.59
Free cash flow $88.4M $101.6M $122.6M $274.3M $203.3M $327.6M
Free cash margin 29% 37% 26% 48% 32% 42%
Cash $174.1M $186.4M $173.7M $238.9M $70.6M $231.3M
Long-term debt $110.0M $61.7M $397.6M $221.7M $550.7M $542.1M
Shareholders' equity $186.0M $202.9M $194.8M $195.4M $228.8M $301.7M
Shares outstanding 34.61m 33.66m 33.85m 31.87m 31.44m 31.71m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Aug 6, 2026 Quarterly ↗ Jun 30, 2026 37d
May 7, 2026 Quarterly ↗ Mar 31, 2026 37d
Feb 26, 2026 Annual ↗ Dec 31, 2025 57d
Nov 6, 2025 Quarterly ↗ Sep 30, 2025 37d
Aug 7, 2025 Quarterly ↗ Jun 30, 2025 38d
May 8, 2025 Quarterly ↗ Mar 31, 2025 38d
Feb 27, 2025 Annual ↗ Dec 31, 2024 58d
Nov 7, 2024 Quarterly ↗ Sep 30, 2024 38d
Aug 8, 2024 Quarterly ↗ Jun 30, 2024 39d
May 9, 2024 Quarterly ↗ Mar 31, 2024 39d
Feb 22, 2024 Annual ↗ Dec 31, 2023 53d
Nov 7, 2023 Quarterly ↗ Sep 30, 2023 38d

Current reports

FiledDisclosed
Oct 19, 2026 Agreement ended ↗
Aug 13, 2026 Other events ↗
Aug 6, 2026 Results · Regulation FD ↗
May 15, 2026 Shareholder vote ↗
May 12, 2026 Acquisition or disposal · Director or officer change · Regulation FD ↗
May 7, 2026 Results · Regulation FD ↗
Apr 7, 2026 Director or officer change ↗
Mar 19, 2026 Material agreement · Regulation FD ↗
Feb 26, 2026 Results · Regulation FD ↗
Jan 8, 2026 Regulation FD ↗
Dec 30, 2025 Material agreement · Agreement ended · Unregistered share sale · Regulation FD ↗
Nov 6, 2025 Results · Regulation FD ↗